 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
This undiscovered low float stock is brutally undervalued alone the Marketed drugs which are in early stage of the launch phase will drive this Company into profitability within 2 years They have 5 Marketed Products and awaiting Phase 2 results of their Oral thin-film Insulin in April which has Multi Billion Dollar Potential and many other Drugs in clinical Trials . If the Phase 2 results of the Oralfilm Insulin in April is positive then this low float stock could triple or quadruple within days . This Undiscovered Stock with a Market Cap of less than $60 Million and over $30 Million in Cash is heavily underpriced but this will Change very soon especially when the Outcome of the Oralfilm Insulin is positive .GL Midatech Pharma (MTP) Market Cap: $59.5 Million Cash: $35 Million Price: $3.58 Shares Out: 16.6 Million MidatechPharma US: Focus On Oncology and Supportive Care: Zuplenz: Oral film for Chemo/Radio Rx Induced Nausea & Vomiting Highly effective 5HT3 antagonist Launch H1 2016 Gelclair: Hyaluronic Acid Oral Gel For Oral Mucositis 85-100% of H&N cancer patients on chemo/radiotherapy develop OM Leads market in US strong growth expected 2016 Aquoral:Oral Spray Treatment For Dry Mouth Xerostomia Oravig:Buccal Tablet For Oral Candidiasis In Adults Serious complication for patients undergoing radio/chemotherapy Launched H2 2015 –first full year of sales 2016 Ferralet90: Dual Iron Delivery Anaemia treatment Oral thin-film Insulin: From positive Phase I clinical trial results it has been demonstrated that the transbuccal insulin formulation is safe and well tolerated in healthy human volunteers and that it is absorbed faster and utilised more quickly than subcutaneous insulin. •Phase I (2012) -No safety concerns -Suggests insulin enters blood, faster to max effect •Phase IIa-Completed in life phase January 2016 -Clinical Study Report is expected in April 2016 •Phase II data will inform strategic opportunities (license or exit) “Diabetes incidence is forecast to hit 500m people, globally, by 2025; with our partnered transbuccal insulin strip, MSL-001 is targeting a $20 billion market, adding significant revenue potential to our growing portfolio of products.” Jim Phillips Presents on behalf of Midatech Pharma at the Biotech Capital Conference youtube.com March Presentation midatechpharma.com Major shareholders midatechpharma.com Edison Research edisoninvestmentresearch.com Valuation: Increased to $221.0m from $200.7m Our valuation for Midatech increases to $221.0m from $200.7m previously (or $13.29/ADR from $14.45/ADR, as we now incorporate the acquisitions of DARA and Zuplenz. Our valuation for DARA is based on forecast future operating cash flows (excluding potential payments on contingent value rights that are dependent on sales milestones, which exceed our relatively conservative projections). Additionally, we adjust our valuation for Midatech upward as our model has been rolled forward by six months and rebased to 2016.  | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |